Can a patch stop Implant-Related bleeding? new trial aims to find out

NCT ID NCT07083635

Recruiting now Symptom relief Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a transdermal patch containing ethinyl estradiol and norelgestromin can stop irregular vaginal bleeding in women using contraceptive implants. Forty women over 18 who have abnormal bleeding will apply the patch or a placebo for 21 days. Researchers will check if bleeding stops by day 14 and monitor side effects and recurrence for 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ethinyl estradiol and norelgestromin patch
What this could lead to: If it works, this could offer a simple, short-term patch treatment to stop irregular bleeding caused by contraceptive implants.
What could go wrong: This is a small, early-phase trial with only 40 participants. The patch may not work better than placebo, and side effects from hormones are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRACEPTION BEHAVIOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Contraception Behavior menstrual disorder Menstruation Disturbances Metrorrhagia Uterine Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRACEPTION BEHAVIOR MENSTRUATION DISTURBANCES METRORRHAGIA UTERINE HEMORRHAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Family Planning Clinic, King Chulalongkorn Memorial Hospital
RECRUITING

Pathum Wan, Bangkok, 10400, Thailand

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.